This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Add-on therapy for the treatment of refractory complex partial seizures in children 10 years of age and older who have inadequately responded to several other treatments and if the possible benefit outweighs the risk of vision loss s the dose in milligrams (mg) and milliliters (mL) is not confused; s the dosing is based on weight for patients under 50 kg; s infusion pumps are properly programmed; and s the total daily dose of acetaminophen from all sources does not exceed maximum daily limits. • Ofirmev contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the maximum daily limits and often involve more than one acetaminophen-containing product. WARNINGS AND PRECAUTIONS Hepatic Injury
• The maximum recommended daily dose of acetaminophen includes all routes of acetaminophen administration and all acetaminophen-containing products administered, including combination products.
Serious Skin Reactions
• Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs of serious skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.
Risk of Medication Errors
• Take care when prescribing, preparing, and administering Ofirmev (acetaminophen) injection in order to avoid dosing errors that could result in accidental overdose and death. In particular, be careful to ensure that: s the dose in mg and mL is not confused; s the dosing is based on weight for patients under 50 kg; s infusion pumps are properly programmed; and s the total daily dose of acetaminophen from all sources does not exceed maximum daily limits. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm373724.htm (continued) 
WARNINGS AND PRECAUTIONS Gastrointestinal-Related Adverse Reactions in Opioid-Tolerant Patients
• Patients recently exposed to opioids are expected to be more sensitive to the effects of mm-opioid receptor antagonists, such as Entereg.
Risk of Serious Adverse Reactions in Patients with Severe Hepatic Impairment
• Patients with severe hepatic impairment may be at higher risk of serious adverse reactions (including dose-related serious adverse reactions) because up to 10-fold higher plasma levels of drug have been observed in such patients compared with patients with normal hepatic function. Therefore, the use in this patient population is not recommended.
Risk of Serious Adverse Reactions in Patients with Complete Gastrointestinal Obstruction
• No studies have been conducted in patients with complete gastrointestinal obstruction or in patients who have surgery for correction of complete bowel obstruction. Entereg is not recommended for use in these patients.
Risk of Serious Adverse Reactions in Pancreatic and Gastric Anastomoses
• Entereg has not been studied in patients having pancreatic or gastric anastomosis. Therefore, Entereg is not recommended for use in these patients. • Dose-dependent prolongations in PR interval with Vimpat have been observed in clinical studies in patients and in healthy volunteers. In clinical trials in patients with partial-onset epilepsy, asymptomatic first-degree atrioventricular (AV) block was observed as an adverse reaction in 0.4% (4/944) of patients randomized to receive Vimpat and 0% (0/364) of patients randomized to receive placebo. In clinical trials patients with diabetic neuropathy, asymptomatic firstdegree AV block was observed as an adverse reaction in 0.5% (5/1023) of patients receiving Vimpat and 0% of patients receiving placebo. In the uncontrolled extension phases of pain studies, 2 subjects[sponsor to fill in denominator of trial patients] experienced AV block type 2. Neither of these subjects had 2nd degree block at baseline although both had either PR prolongation or 1st degree AV block at baseline. In one of these cases, the block was found as result of monitoring performed after an episode of syncope. When Vimpat is given with other drugs that prolong the PR interval, further prolongation is possible. Vimpat should be used with caution in patients with known conduction problems (eg, marked 1st-degree AVB, 2nd-degree or higher AVB and sick sinus syndrome without pacemaker, with sodium channelopathies (eg, Brugada Syndrome) on concomitant medications that prolong PR interval, or with severe cardiac disease such as myocardial ischemia or heart failure. In such patients, obtaining an ECG before beginning Vimpat, and after Vimpat is titrated to steady state, is recommended. ADVERSE REACTIONS Postmarketing Experience:
• The following adverse events have been reported during post-approval use of Vimpat. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Due to the need to balance the benefit of adding potentially serious medical events to the label and the risk that doing so will discourage future reporting of such events, health care providers and consumers are encouraged to continue reporting such events regardless of whether the event is already in this section. Warning intoxication (respiratory compromise or arrest, circulatory collapse, etc) if the patient uses previously tolerated doses of opioids. Cases of opioid overdose with fatal outcomes have been reported in patients after discontinuing treatment. • Patients should be alerted that they may be more sensitive to opioids, even at lower doses, after Revia treatment is discontinued. It is important that patients inform family members and the people closest to the patient of this increased sensitivity to opioids and the risk of overdose. • There is also the possibility that a patient who is treated with Revia could overcome the opioid blockade effect of Revia. Although Revia is a potent antagonist, the blockade produced by Revia is surmountable. The plasma concentration of exogenous opioids attained immediately following their acute administration may be sufficient to overcome the competitive receptor blockade. This poses a potential risk to individuals who attempt, on their own, to overcome the blockade by administering large amounts of exogenous opioids. Any attempt by a patient to overcome the antagonism by taking opioids is especially dangerous and may lead to life-threatening opioid intoxication or fatal overdose. Patients should be told of the serious consequences of trying to overcome the opioid blockade Precipitated Opioid Withdrawal
• The symptoms of spontaneous opioid withdrawal (which are associated with the discontinuation of opioid in a dependent individual) are uncomfortable, but they are not generally believed to be severe or necessitate hospitalization. However, when withdrawal is precipitated abruptly by the administration of an opioid antagonist to an opioid-dependent patient, the resulting withdrawal syndrome can be severe enough to require hospitalization. Symptoms of withdrawal have usually appeared within 5 minutes of ingestion of Revia and have lasted for up to 48 hours. Mental status changes including confusion, somnolence, and visual hallucinations have occurred. Hepatotoxicity
• Cases of hepatitis and clinically significant liver dysfunction were observed in association with Revia exposure during the clinical development program and in the postmarketing period. Transient, asymptomatic hepatic transaminase elevations were also observed in the clinical trials and postmarketing period. When patients presented with elevated transaminases, there were often other potential causative or contributory etiologies identified, including pre-existing alcoholic liver disease and hepatitis B and/or C infection.
Depression and Suicidality
• Depression, suicide, attempted suicide, and suicidal ideation have been reported in the postmarketing experience with Revia (naltrexone hydrochloride) used in the treatment of opioid dependence. No causal relationship has been demonstrated. In the literature, endogenous opioids have been theorized to contribute to a variety of conditions. • Alcohol-and opioid-dependent patients, including those taking Revia, should be monitored for the development of depression or suicidal thinking. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm374896.htm Naratriptan Amerge (GlaxoSmithKline)
CONTRAINDICATIONS
• Hypersensitivity to Amerge (angioedema and anaphylaxis seen).
WARNINGS AND PRECAUTIONS Increase in Blood Pressure
• Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT1 agonists, including patients without a history of hypertension. Monitor blood pressure in patients treated with Amerge. Amerge is contraindicated in patients with uncontrolled hypertension.
(continued) Suspended marketing and sales because of the risk of life-threatening blood clots and severe narrowing of blood vessels. FDA will continue to evaluate the drug to further understand its risks and potential patient populations in which the benefits of the drug may outweigh the risks. Patients currently receiving ponatinib should discuss the risks and benefits of continuing treatment with the drug with their prescriber. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm373072.htm? source5govdelivery&utm_medium5email&utm_source5govdelivery CONTRAINDICATIONS Janumet (sitagliptin/metformin HCl) is contraindicated in patients with:
• Renal impairment (eg, serum creatinine levels greater than or equal to 1.5 mg/dL for men, greater than or equal to 1.4 mg/dL for women or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia. • Hypersensitivity to metformin hydrochloride.
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Diabetic ketoacidosis should be treated with insulin. WARNINGS AND PRECAUTIONS Lactic Acidosis Metformin hydrochloride
• The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is very low (approximately 0.03 cases/1,000 patient-years, with approximately 0.015 fatal cases/1,000 patient years). In more than 20,000 patient-years exposure to metformin in clinical trials, there were no reports of lactic acidosis. Reported cases have occurred primarily in diabetic patients with significant renal impairment, including both intrinsic renal disease and renal hypoperfusion, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. In addition, metformin should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis.
Assessment of Renal Function
• Therefore, Janumet is contraindicated in patients with renal impairment. Sitagliptin
• There have been postmarketing reports of worsening renal function, including acute renal failure, sometimes requiring dialysis. Before initiation of therapy with Janumet and at least annually thereafter, renal function should be assessed and verified as normal. In patients in whom development of renal dysfunction is anticipated, particularly in elderly patients, renal function should be assessed more frequently and Janumet discontinued if evidence of renal impairment is present.
DRUG INTERACTIONS Carbonic Anhydrase Inhibitors
• Topiramate or other carbonic anhydrase inhibitors (eg, zonisamide, acetazolamide or dichlorphenamide) frequently decrease serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs may induce metabolic acidosis. Use these drugs with caution in patients treated with Janumet, as the risk of lactic acidosis may increase.
(continued) Warning USE IN SPECIFIC POPULATIONS Renal Impairment • "insufficiency" changed to "impairment" Hepatic Impairment
• "insufficiency" changed to "impairment" http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm372690.htm Tacrolimus Prograf (Astellas)
WARNINGS AND PRECAUTIONS Use with CYP3A4 Inhibitors and Inducers
• When coadministering Prograf with strong CYP3A4-inhibitors (eg, telaprevir, boceprevir, ritonavir, ketoconazole, itraconazole, voriconazole, clarithromycin) and strong inducers (eg, rifampin, rifabutin), adjustments in the dosing regimen of Prograf and subsequent monitoring of tacrolimus whole blood trough concentrations and tacrolimus-associated adverse reactions are recommended.
QT Prolongation
• Prograf may prolong the QT/QTc interval and may cause torsade de pointes. Avoid Prograf in patients with congenital long QT prolongation syndrome.
In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.
• When coadministering Prograf with other substrates and/or inhibitors of CYP3A4 that also have the potential to prolong the QT interval, a reduction in Prograf dose, frequent monitoring of tacrolimus whole blood concentrations, and monitoring for QT prolongation is recommended. Use of Prograf with amiodarone has been reported to result in increased tacrolimus whole blood concentrations with or without concurrent QT prolongation.
Gastrointestinal Perforation
• Gastrointestinal perforation has been reported in patients treated with tacrolimus; all reported cases were considered to be a complication of transplant surgery or accompanied by infection, diverticulum, or malignant neoplasm. As gastrointestinal perforation may be serious or life threatening, appropriate medical/surgical management should be instituted promptly.
ADVERSE REACTIONS • Gastrointestinal perforation DRUG INTERACTIONS
• Dose adjustments may be needed along with frequent monitoring of tacrolimus whole blood trough concentrations when Prograf is administered with CYP3A inhibitors or inducers. In addition, patients should be monitored for adverse reactions including changes in renal function and QT prolongation. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm295069.htm
Telaprevir
Incivek (Vertex Pharmaceuticals)
CONTRAINDICATIONS
• • In clinical trials in HIV-1 infected adults, Viread/Stribild/Truvada/Complera/ Atripla was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher in subjects receiving Viread/Stribild/Truvada/Complera/ Atripla. • Clinical trials evaluating Viread in pediatric and adolescent subjects were conducted.
Mineralization Defects:
• Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and that may contribute to fractures, have been reported in association with the use of Viread/Stribild/Truvada/Complera/Atripla. Arthralgias and muscle pain or weakness have also been reported in cases of proximal renal tubulopathy. Hypophosphatemia and osteomalacia secondary to proximal renal tubulopathy should be considered in patients at risk of renal dysfunction who present with persistent or worsening bone or muscle symptoms while receiving products containing tenofovir DF.
ADVERSE REACTIONS Adverse Reactions from Clinical Trials Experience Changes in Bone Mineral Density:
• Clinical trials in HIV-1-infected children and adolescents evaluated BMD changes.
In Study 321 (12 to less than 18 years), the mean rate of BMD gain at week 48 was less in the • Combination hormonal contraceptives are known to increase the risk of venous thromboembolism, as well as arterial thromboses such as stroke and myocardial infarction. Because Lysteda is antifibrinolytic, the risk of venous thromboembolism, as well as arterial thromboses such as stroke, may increase further when hormonal contraceptives are administered with Lysteda. This is of particular concern in women who are obese or smoke cigarettes, especially smokers over 35 years of age. • Women using hormonal contraception were excluded from the clinical trials supporting the safety and efficacy of Lysteda, and there are no clinical trial data on the risk of thrombotic events with the concomitant use of Lysteda with hormonal contraceptives. However, there have been US postmarketing reports of venous and arterial thrombotic events in women who have used Lysteda concomitantly with combination hormonal contraceptives. For this reason, concomitant use of Lysteda with combination hormonal contraceptives is contraindicated.
(continued) Treatment failure and excess mortality were observed when trimethoprimsulfamethoxazole was used concomitantly with leucovorin for the treatment of HIV-positive patients with P. jiroveci pneumonia in a randomized placebo-controlled trial. PRECAUTIONS
• Hypoglycemia: -Cases of hypoglycemia in non-diabetic patients treated with sulfamethoxazole/trimethoprim are seen rarely, usually occurring after a few days of therapy. • Phenylalanine metabolism: -Trimethoprim has been noted to impair phenylalanine metabolism, but this is of no significance in phenylketonuric patients on appropriate dietary restriction. • Porphyria and Hypothyroidism: -As with all drugs containing sulfonamides, caution is advisable in patients with porphyria or thyroid dysfunction. Use in the Treatment of and Prophylaxis for P. jiroveci Pneumonia in Patients with Acquired Immunodeficiency Syndrome (AIDS):
• AIDS patients may not tolerate or respond to Septra in the same manner as non-AIDS patients. • Co-administration of Septra and leucovorin should be avoided with P. jiroveci pneumonia • Electrolyte Abnormalities: High dosage of trimethoprim, as used in patients with P. jiroveci pneumonia, induces a progressive but reversible increase of serum potassium concentrations in a substantial number of patients.
Drug Interactions
• Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 transporter. Sulfamethoxazole is an inhibitor of CYP2C9. Caution is recommended when Septra is co-administered with drugs that are substrates of CYP2C8 and 2C9 or OCT2. • Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations.
(continued)
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Volume 49, January 2014 with Septra. • Septra potentiates the effect of oral hypoglycemics that are metabolized by CYP2C8 (eg, pioglitazone, repaglinide, and rosiglitazone) or CYP2C9 (eg, glipizide and glyburide) or eliminated renally via OCT2 (eg, metformin). Additional monitoring of blood glucose may be warranted. • In the literature, a single case of toxic delirium has been reported after concomitant intake of sulfamethoxazole/trimethoprim and amantadine (an OCT2 substrate). Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported. • In the literature, 3 cases of hyperkalemia in elderly patients have been reported after concomitant intake of sulfamethoxazole/trimethoprim and an angiotensin-converting enzyme (ACE) inhibitor. Carcinogenesis, Metagenesis, Impairment of Fertility Carcinogenesis
• Sulfamethoxazole was not carcinogenic when assessed in a 26-week tumorigenic mouse (Tg-rasH2) study at doses up to 400 mg/kg/day sulfamethoxazole; equivalent to 2.4-fold the human systemic exposure (at a daily dose of 800 mg sulfamethoxazole bid).
Mutagenesis
• In vitro reverse mutation bacterial tests according to the standard protocol have not been performed with sulfamethoxazole and trimethoprim in combination. Pregnancy Impairment of Fertility • Doses roughly 2 times the recommended human daily dose on a body surface area basis. Teratogenic Effects: Pregnancy Category D • Human Data: While there are no large prospective, well-controlled studies in pregnant women and their babies, some retrospective epidemiologic studies suggest an association between first trimester exposure to sulfamethoxazole/ trimethoprim with an increased risk of congenital malformations, particularly neural tube defects, cardiovascular abnormalities, urinary tract defects, oral clefts, and club foot. • Animal Data: In rats, oral doses of either 533 mg/kg sulfamethoxazole or 200 mg/kg trimethoprim produced teratologic effects manifested mainly as cleft palates.
Nursing Mothers
• Levels of trimethoprim/sulfamethoxazole in breast milk are approximately 2%-5% of the recommended daily dose for infants over 2 months of age.
Pediatric Use
• Septra is contraindicated for pediatric patients younger than 2 months of age.
ADVERSE REACTIONS Genitourinary
• Nephrotoxicity in association with cyclosporine.
(continued) The following adverse reactions have been identified during post-approval use of trimethoprim-sulfamethoxazole. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure:
• Thrombotic thrombocytopenia purpura • Idiopathic thrombocytopenic purpura • QT prolongation resulting in ventricular tachycardia and torsade de pointes http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm370057.htm Valsartan Diovan (Novartis)
CONTRAINDICATIONS
• Do not coadminister aliskiren with Diovan in patients with diabetes WARNINGS AND PRECAUTIONS Fetal Toxicity
• Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Diovan as soon as possible.
DRUG INTERACTIONS
• Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on Diovan and other agents that affect the RAS. • Do not coadminister aliskiren with Diovan in patients with diabetes. Avoid use of aliskiren with Diovan in patients with renal impairment (GFR ,60 mL/min).
USE IN SPECIFIC POPULATIONS
• Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Diovan as…[sic] Pediatric Use Neonates with a history of in utero exposure to Diovan: If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm262225.htm ZIV-aflibercept Zaltrap (sanofi-aventis)
WARNINGS AND PRECAUTIONS Proteinuria
• Monitor proteinuria by urine dipstick analysis and/or urinary protein creatinine ratio (UPCR) for the development or worsening of proteinuria during Zaltrap therapy. Patients with a dipstick of 521 for protein or a UPCR greater than 1 should undergo a 24-hour urine collection. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm374591.htm a Practitioners are encouraged to check the FDA's MEDWATCH Web site (http://www.fda.gov/medwatch/safety.htm) for updated information.
